食管鳞癌组织中Nrf2和Bcl-2蛋白表达的关系及其临床意义

doi:10.3969/j.issn.1004-616x.2014.06.004

Abstract

Abstract:

OBJECTIVE: To investigate the expressions of Nrf2 and Bcl-2 and clinical pathological features in esophageal carcinoma tissues. METHODS：Immunohistochemistry (SP) and Western blot were used to detect the expressions of Nrf2 and Bcl-2 in 85 specimens of esophageal carcinoma tissues and normal esophageal tissues (5 cm distant to the margin of esophageal cancer). RESULTS：The positive rates of Nrf2 and Bcl-2 protein(83.5% and 72.9%， respectively) in esophageal carcinoma tissues were both higher than normal tissues(14.2% and 5.7%， respectively)(P< 0.01). The relative contents of Nrf2 and Bcl-2 protein(0.855±0.078 and 0.801±0.075，respectively) in esophageal carcinoma tissues were both higher than normal tissues (0.135±0.011 and 0.173±0.040，respectively) (P<0.01). There was a significant difference in Nrf2 protein expressions between lesion length，depth of invasion， histological grade and lymph node metastasis (P<0.05)，but not correlated with lesion location and general classification of tumors (P>0.05). Spearman analysis showed that Nrf2 protein expression was positively correlated with Bcl-2 protein expression (r=0.515，P=0.000). CONCLUSION：Nrf2 and Bcl- 2 protein expression could be considered as biological indicators of the malignant potential of esophageal squamous carcinoma.

Key words: Nrf2, Bcl-2, esophageal , squamous , cell , carcinoma, immunohistochemistry, Western , blot

ZHANG Jun，KONG Jie，ZHANG An-du，KONG De-you，ZHANG Jian. The relationship between the expression and clinical significance of Nrf2 and Bcl-2 in esophageal squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2014.06.004.

References

[1] 周渊，王汉东，记祥君，等. RNA干扰下调Nrf2 对U251 细胞自噬的影响[J]. 中华神经外科疾病研究杂志，2013，12 (6)：509-512.

[2] Germano IM，Emdad L，Qadeer ZA，et al. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression，apoptosis and radiosensitization，and overcomes temozolomide resistancein malignant gliomas[J]. Cancer Gene Ther， 2010，17(9) ：664 -674.

[3] Niture SK，Jaiswal AK. Nrf2 up-regulates anti-apoptotic proteinBcl-2 and prevents cellular apoptosis[J]. J Biol Chem， 2012，287(13)：9873-9886.

[4] Kwak MK，Wakabayashi N，Kensler TW. Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers[J]. Mutation Res，2004，555(1/2)：133-148.

[5] McMahon M，Thomas N，ltoh K，et al. Redox-regulated turnover of Nrf2 is determined by at least two spearate protein domains，the redox-sensitive Neh2 degron and the redox- insensi-tive Neh6 degron[J]. J Biol Chem，2004，279(30)： 31556 - 31567.

[6] Hseu YC，Chou CW，Senthil Kumar KJ，et al. Ellagic acid protects human ketatinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation the upregulation of the HO-1 and Nref-2 antioxidan genes[J]. Food Chem Toxicol，2012，50(5)：1245-1255.

[7] 王鹤令，陈安杰，刘鹏，等. Bcl-xl/Bcl-2相关死亡启动因子在肝外胆管癌组织中的表达及意义[J]. 中国医科大学学报，2013，42(12)：1105-1108.

[8] Takahashi T，Sonobe M，Menju T，et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer[J]. J Surg Oncol，2010，101(6)：500-506.

[9] Alexandria Lan，Villeneuve NF，Sun Z，et al. Dual roles of Nrf2 in cancer[J]. Pharmacological Research，2008，(58)： 267-270.

[10] Kim YJ，Ahn JY，Liang P，et al. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation： implication to tumor biology[J]. Cancer Res，2007，67(2)： 546-554.

[11] Nioi P，Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity[J]. Biochem Biophys Res Commun，2007，362：816-821.

[12] Wang XJ，Sun Z，Villeneuve NF，et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs，the dark side of Nrf2[J]. Carcinogenesis，2008，29：1235-1243.

[13] Cho JM，Manandhar S，Lee HR，et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin：Implication to cancer cell resistance[J]. Cancer Lett， 2008，260：96-108.

[14] Kim SK，Yang JW，Kim MR，et al. Increased expression of /ARE-dependent antioxidant proteins in tamoxifen-resistant breast cancer cells[J]. Free Radic Biol Med，2008，45：537-546.

[15] Wang JH，Du JP，Zhang YH，et al. Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance[J]. World J Gastroenterol，2011，17(35)： 3986-3993.

The relationship between the expression and clinical significance of Nrf2 and Bcl-2 in esophageal squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Xinping, JIA Di, LIN Shaohui, LIU Chen, LI Jingyi, ZHAO Weiming. Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 47-52,66.
[2]	GUO Zhaomeng, ZHANG Hua, ZHANG Peng. Mechanisms of Orai1 on invasion and epithelial-mesenchymal transformation in nasopharyngeal carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 420-425.
[3]	ZHANG Zongming. Does thyroid microcarcinoma require surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 325-326.
[4]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effects of HMGB1 silencing on migration, invasion and radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 327-333.
[5]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[6]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[7]	CHANG Chen, YANG Liyan, CAI Hongqing, YUAN Qing, HAO Jiajie, WANG Mingrong. Expressions and clinical implications of SERPINE1 mRNA in esophageal squamous carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 245-249.
[8]	ZENG Zhuoying, WU Desheng, LU Jingjing, LIAO Hui, LAI Hongpiao, YUAN Jianhui, HU Zhangli. Mediation by estrogen receptor α on oxidative phosphorylation pathways in development of lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 262-268.
[9]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[10]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[11]	CHEN Tingyu, CHEN Dayin, XIE Jinlu, GAO Xiren, LU Chunfeng. Role of the Nrf2/ARE signaling pathway on quercetin-inhibition of INH-induced mitochondrial oxidative damage in hepatocytes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 208-212,217.
[12]	JIAO Wenjing, GUO Xiujuan, SHAO Junguo, JIAO Wenpeng, ZHANG Jinyan. Relationships among blood cell ratios, clinicopathological characteristics and prognosis in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 213-217.
[13]	ZHANG Die, LIU Xianghe, HUO Miaomiao, LIU Mei, XU Ningzhi, ZHU Hongxia. Effects of miR-195-5p on radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 81-88,94.
[14]	ZHANG Na, FAN Zhilu, YANG Liyan, CHANG Chen, CAI Yan, HAO Jiajie, WANG Mingrong. Clinical significance of decreased SERPINB5 expression in esophageal squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 101-109.
[15]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.